Full Text Journal Articles in
Journal Cancer Res

Advertisement

Find full text journal articles






Efficacy of CD40 agonists is mediated by distinct cDC subsets and subverted by suppressive macrophages.

Aleksandar Murgaski, Máté Kiss, Helena Van Damme, Daliya Kancheva, Isaure Vanmeerbeek, Jiri Keirsse, Eva Hadadi, Jan Brughmans, Sana M Arnouk, Ahmed E I Hamouda, Ayla Debraekeleer, Victor Bosteels, Yvon Elkrim, Louis Boon, Sabine Hoves, Niels Vandamme, Sofie Deschoemaeker, Sophie Janssens, Abhishek D Garg, Greetje Vande Velde, Martina Schmittnaegel, Carola H Ries, Damya Laoui,

Agonistic αCD40 therapy has been shown to inhibit cancer progression in only a fraction of patients. Understanding the cancer cell-intrinsic and microenvironmental determinants of αCD40 therapy response is therefore crucial to identify responsive patient populations and design efficient combinatorial treatments. Here, we show that the therapeutic efficacy of αCD40 in ... Read more >>

Cancer Res (Cancer research)
[2022, :CAN-22-0094]

Cited: 0 times

View full text PDF listing >>



Targeting STAT5 signaling overcomes resistance to IDH inhibitors in acute myeloid leukemia through suppression of stemness.

Alex C H Liu, Severine Cathelin, Yitong Yang, David L Dai, Dhanoop Manikoth Ayyathan, Mohsen Hosseini, Mark D Minden, Anne Tierens, Steven M Chan,

Mutant isocitrate dehydrogenase 1 (IDH1) and IDH2 block the differentiation of acute myeloid leukemia (AML) cells through production of R-2-hydroxyglutarate (R-2-HG). IDH inhibitors can induce differentiation of AML cells by lowering R-2-HG but have limited clinical efficacy as single agents. Here, we performed a genome-wide CRISPR knockout screen in an ... Read more >>

Cancer Res (Cancer research)
[2022, :CAN-22-1293]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

0.6849 s